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An Individual Approach to Thrombolytic Therapy in Patients with Evolving 
Myocardial Infarction 
M. L. Simoons, E. Boersma 
In recent years different regimens for reperfusion ther- 
apy in evolving myocardial infarction have been de- 
veloped: intravenous streptokinase, accelerated tPA and 
direct angioplasty. The life saving effect of thrombolytic 
therapy has been established in a number of randomized 
trials, most of which tested streptokinase 1.5 million 
units administered over l h. The results have been sum- 
marized in the report of the fibrinolytic therapy trialists. 1 
In patients treated within 6 h after the onset of symptoms 
an overall treatment benefit of 28% has been observed, 
while a smaller benefit (12.5%) can be achieved by treat- 
ment between 6 and 12 h after symptom onset. 2'3 
Two studies howed no difference between streptoki- 
nase and alteplase or duteplase given without heparin or 
with delayed administration f subcutaneous heparin. 4'5 
In contrast, the GUSTO study clearly demonstrated im- 
proved survival (mortality reduction 18%) by accel- 
erated tPA, administered over 90 min, with high dose 
intravenous heparin. 6 The GUSTO angiographic sub- 
study confirmed that a greater benefit by accelerated tPA 
was caused by higher early reperfusion rates obtained by 
that regimen, while later patency rates (3 h or more after 
onset of therapy) were similar for the different 
regimens. 7'8 
Three recent studies have shown more rapid reperfu- 
sion by direct angioplasty, associated with better survival 
compared with thrombolytic therapy. 9-12 The proportion 
of patients with adequate (TIMI grade III) perfusion at 
various intervals after the onset of therapy is illustrated 
in Figure I. 
Unfortunately the more effective regimens (accel- 
erated tPA versus streptokinase and direct angioplasty 
versus thrombolytic therapy) are also more expensive 
and more complex. Because of budgetary constrains it
will often not be possible to provide the best (and most 
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expensive) therapy to all patients. In this paper we pres- 
ent a model which may help to allocate different modes 
of therapy to specific groups of patients with evolving 
myocardial infarction in a rational way. 
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Fig. 1 Graphic display of Thrombolysis in Myocardial Infarction 
(TIMI) grade 3 flow immediately after randomization: comparison of 
the angiographic results from the Zwolle and GUSTO trials. The data 
on TIMI flow in the GUSTO trial were gathered from different 
patients, who were randomly assigned to angiography at different time 
intervals after start of therapy. GUSTO indicates the Global Utilization 
of Streptokinase and Tissue plasminogen activator for Occluded 
Coronary Arteries Study; tPA indicates tissue plasminogen activator; 
SK indicates streptokinase. From: Chapter 5, Thesis M.J. de Boer, 
1994, p 128. 
16 
Currently available data indicate a proportional re- 
duction of mortality by reperfusion therapy (compared 
with conventional treatment or placebo) and by accel- 
• 1--6 erated tPA compared with streptokmase. Thus the 
greatest benefit in absolute terms (lives saved) will be 
achieved in patients with the greatest mortality risk. A 
model to predict early (1 year) mortality in different pa- 
tient subgroups i presented in Figure 2. This model has 
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Fig. 2 Estimated probability of death without and with (early) reperfusion therapy. From top to bottom subgroups of patients are presented without r 
with one to three indicators for increased mortality risk: age > 60 years, history of previous infarction, anterior location of infarction, inferior 
infarction with right ventricular involvement, presence of congestive heart failure, QRS duration > 120 ms. In each of these four subgroups, patients 
are subdivided according to the extent of ST segment deviation (elevation and depression) in the combined 12 leads: > or < 2 mV (= 20 mm on 
standard calibration). 
Data derived from four studies as presented in reference 13. Low mortality risk (13.1-4.5%) in a subgroup of 25% of patients without risk 
indicators. Mortality risk 35-44% in a subgroup of 9% of patients with ree or more risk indicators. 
One year mortality without reperfusion therapy is indicated by the length of the bars. Early reperfusion therapy (within 3 h of symptom onset) will 
reduce mortality by 50%, the remaining mortality is indicated by the dark portion of the bars, the number of patients aved is indicated by the light 
portion of the bars. 
been derived by multivariable analysis using data from 4 
different placebo controlled studies.13 In patients with a 
small infarct without additional risk indicators (a sub- 
group including 25% of patients enrolled in these trials) 
I year mortality will be less than 5%. In contrast, mor- 
tality may be as high as 25% or greater in patients with 
multiple risk indicators (9% of trial population). 
In view of this gradient of benefit in different patient 
subgroups, and the gradient in efficacy of various treat- 
ment regimens it will be most appropriate to apply the 
most effective (most intensive and most expensive) ther- 
apy to patients where the greatest benefit may be ex- 
pected. Furthermore, medical ethics imply that patients 
with similar expected benefit should receive the same 
treatment, irrespective of their financial or social status, 
and irrespective of their age. In order to apply this prin- 
ciple a yardstick must be developed to assess the ex- 
pected benefit of various modes of reperfusion therapy, 
depending on the patients characteristics. With such 
yardstick patients can be ranked in order of the expected 
benefit, and patients groups with the greatest expected 
benefit may be allocated to more intensive (and more ex- 
pensive) therapy while a less intensive (and less expens- 
ive) therapy may be provided to patients with a smaller 
expected benefit. The best outcome parameter for such 
yardstick would be the expected gain in life years after 
therapy. 
ESTIMATION OF THE EXPECTED GAIN IN 
LIFE YEARS BY REPERFUSION THERAPY 
The expected gain in lives may be computed in a two 
step approach. First, assessment of the life years gained 
in the first year after treatment for myocardial infarction 
and subsequently assessment of life expectancy of survi- 
vors. 
The initial (1 year) gain in life years can be derived 
from the model presented in Figure 2. Subsequently, 
long term survival (after the first year) can be estimated 
using: 
* Survival curves 
• Survival tables of the normal reference population in 
various age groups. In The Netherlands, life expec- 
tancy in subjects at an average age of 55 years is 
22.0 years, while this is 14.3 years and 8.4 years in 
subjects at an age of 65 and 75 years, respectively. 
• Follow up data up to 5 or 10 years from trials with 
reperfusion therapy. These indicate that yearly mor- 
tality after myocardial infarction exceeds average 
yearly mortality in a population by approximately 
1.5%. 14,15 
• Late mortality will continue to be greater in patients 
with extensive damage after a large infarction, and 
will be smaller in patients with preserved cardiac 
function after a limited infarct. 
• In studies of cost efficacy analysis it is customary to 
give a higher weight to the near future compared to 
the more distant future. Thus future life years are 
discounted, usually with a rate of 5% per year. This 
discounting procedure also reflects the fact that 
early treatment outcome can be predicted more ac- 
curately than late outcome. In contrast, no value 
judgement is made comparing different age groups. 
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Thus the next 5 years of a 70 year old (from 70 to 
75) are given the same weight as the next 5 years of 
a 50 year old person (between 50 and 55 years). The 
higher mortality rate at advanced age is taken into 
account using the above mentioned specific popula- 
tion derived life expectancy figures. 
ing risk may outweigh the possible benefits of thrombo- 
lytic therapy. Also, the increased risk should be taken 
into account in patients at advanced age with multiple 
bleeding risk indicators. 
ALLOCATION OF RESOURCES 
The results of the analysis as described above are 
presented in the Table. A more extensive set of tables 
has been developed and is currently under evaluation in 
our institution as well as several other cooperating hospi- 
tals. 
INTRACRANIAL BLEEDING RISK 
Intracranial bleeding is infrequent in patients with myo- 
cardial infarction without thrombolytic therapy, while 
bleeding risk is increased with such therapy. Patients re-
ceiving standard streptokinase therapy have an intracra- 
nial bleeding risk of 0.5-1.0%, while this risk is slightly. 
higher in patients treated with accelerated tPA. 6"16 
Through multivariable analysis of data from different 
trials the following risk factors for intracranial bleeding 
were identified: advanced age, hypertension at the time 
of hospital admission, low body weight, and use of alte- 
16 plase compared with streptokinase. Furthermore, 
bleeding risk is increased in patients with previous cere- 
brovascular disease, and patients with a recent cranial 
trauma, for example those who fainted from arrhythmias 
during the infarct. In larger trials, the total risk of stroke 
after thrombolytic therapy was similar to the risk of 
stroke without such therapy. In fact, the risk of embolic 
stroke is reduced by thrombolytic therapy as a result of 
limitation of infarct size and the anticoagulant effect of 
the thrombolytic agents. The reduced embolic stroke rate 
compensates the increased incidence of intracranial he- 
morrhage. 
It should be appreciated that the benefit of thrombo- 
lytic therapy in most patients far outweighs the intracra- 
nial bleeding risk. Similarly, the benefit of therapy with 
accelerated tPA over streptokinase is approximately 10- 
fold greater than the increased bleeding risk by tPA. 6 
Only in patients with a small infarct an increased bleed- 
Data such as presented in Table provide an objective 
measure of the expected benefit of reperfusion therapy. 
Thus a ranking of patients with different levels of benefit 
is provided. Still, in different hospital environments de- 
cisions must be made which threshold levels to apply for 
various modes of therapy. Such decisions should be 
based on the availability of resources and funds. At the 
Thoraxcenter we have elected to provide direct angio- 
plasty to approximately 10% of patients: those with the 
greatest expected benefit, particularly if they are at in- 
creased risk for intracranial hemorrhage. 16 Accelerated 
tPA and intravenous streptokinase will be applied in ap- 
proximately equal numbers of patients, while no reperfu- 
sion therapy will be provided to a small subgroup of 
patients in whom benefit would be negligible anyhow. 
Other centers may elect different allocation of resources 
and decide to use accelerated tPA (the more effective 
treatment) more frequently than streptokinase, or they 
may elect to use angioplasty in a greater proportion of 
patients. Still the same measure can be used (as 
presented above) applying different threshold values. 
MEDICAL JUDGEMENT PREVAILS 
It should be appreciated that the models to develop the 
decision tables have a limited accuracy. The model pro- 
vides a guideline for medical management, but the 
physician may decide on other treatment, particularly in 
patients with characteristics which have not been in- 
cluded in the model. For example thrombolytic therapy 
should be avoided in patients with recent cranial trauma, 
because of increased intracranial bleeding risk. In such 
patients direct angioplasty would be appropriate, in spite 
of modest expected treatment benefit, if such therapy can 
be made available at short notice. Still, in our experience 
the decision tables are of great help to physicians who 
Table Tailored reperfusion therapy - life expectancy ( ears) 
No Reperfusion Years 
Patient characteristics therapy at 4 h added 
55 yr no MI 22.0 
small MI 16.1 16.1 
large MI 6.2 8.4 2.2 
65 yr no MI 14.3 
small MI 10.7 10.8 0.1 
large M1 4.7 5.6 1.2 
Life expectancy ( ears) in patients aged 55 (top panel) or 65 (bottom panel) years without myocardial infarction with a small infarct, and with 
extensive infarction (anterior infarction with heart failure and extensive ST-segment elevation). No therapy = life expectancy without 
reperfusion therapy. In addition life expectancy with reperfusion therapy at 4 h is indicated as well as the number of life years added by 
reperfusion therapy. 
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often must  make decis ions on the al locat ion of  therapy 
with little t ime for ref lect ion under  diff icult c i rcum- 
stances in the midst  of  the night. 
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